Intellia Therapeutics (NTLA) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $11.34, -0.79% vs the prior close of $11.43.
- Volume 6.52M shares, 1.5x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
NTLA dips 0.8% to $11.34, a 1-month low, 4 down days in a row. Closed at $11.34, -0.79% vs the prior close of $11.43. Day range $11.10–$11.82, opened at $11.33.
NTLA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — NTLA dips 0.8% to $11.34, a 1-month low, 4 down days in a row
- Closed at $11.34, -0.79% vs the prior close of $11.43. Day range $11.10–$11.82, opened at $11.33.
- Volume was 6.52M shares, 1.5x its 50-day average of 4.43M.
- Price is -7.5% vs its 50-day average ($12.25) and -12.7% vs its 200-day average ($12.99).
- 52-week range $7.95–$28.25; today's close sits at 17% of that range, 59.9% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — NTLA slides 4.0% to $11.43, 3 down days in a row
- Closed at $11.43, -4.03% vs the prior close of $11.91. Day range $11.28–$11.87, opened at $11.83.
- Volume was 5.44M shares, 1.2x its 50-day average of 4.41M.
- Price is -6.7% vs its 50-day average ($12.25) and -11.9% vs its 200-day average ($12.98).
- 52-week range $7.95–$28.25; today's close sits at 17% of that range, 59.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — NTLA slides 5.3% to $11.91
- Closed at $11.91, -5.33% vs the prior close of $12.58. Day range $11.81–$12.48, opened at $12.30.
- Volume was 5.18M shares, 1.2x its 50-day average of 4.37M.
- Price is -2.7% vs its 50-day average ($12.24) and -8.1% vs its 200-day average ($12.97).
- 52-week range $7.95–$28.25; today's close sits at 20% of that range, 57.8% below the 52-week high.
Oct 12, 2026 — NTLA slides 3.7% to $12.58
- Closed at $12.58, -3.75% vs the prior close of $13.07. Day range $12.56–$13.23, opened at $13.08.
- Volume was 4.38M shares, 1.0x its 50-day average of 4.34M.
- Price is +2.9% vs its 50-day average ($12.22) and -2.9% vs its 200-day average ($12.95).
- 52-week range $7.95–$28.25; today's close sits at 23% of that range, 55.5% below the 52-week high.
Oct 9, 2026 — NTLA jumps 3.7% to $13.07, a 1-month high on 1.9x normal volume
- Closed at $13.07, +3.73% vs the prior close of $12.60. Day range $11.93–$13.27, opened at $12.36.
- Volume was 8.15M shares, 1.9x its 50-day average of 4.24M — unusually heavy trading.
- Price is +7.3% vs its 50-day average ($12.18) and +1.0% vs its 200-day average ($12.94).
- 52-week range $7.95–$28.25; today's close sits at 25% of that range, 53.7% below the 52-week high.
Oct 8, 2026 — NTLA jumps 7.6% to $12.60 on 3.5x normal volume
- Closed at $12.60, +7.60% vs the prior close of $11.71. Day range $11.76–$12.64, opened at $11.90.
- Volume was 13.97M shares, 3.5x its 50-day average of 4.03M — unusually heavy trading.
- Price is +3.8% vs its 50-day average ($12.14) and -2.5% vs its 200-day average ($12.92).
- 52-week range $7.95–$28.25; today's close sits at 23% of that range, 55.4% below the 52-week high.
Oct 7, 2026 — NTLA slides 5.3% to $11.71 on 2.1x normal volume
- Closed at $11.71, -5.34% vs the prior close of $12.37. Day range $11.70–$12.41, opened at $12.08.
- Volume was 8.30M shares, 2.1x its 50-day average of 3.96M — unusually heavy trading.
- Price is -3.3% vs its 50-day average ($12.11) and -9.3% vs its 200-day average ($12.90).
- 52-week range $7.95–$28.25; today's close sits at 19% of that range, 58.5% below the 52-week high.
Oct 6, 2026 — NTLA dips 3.0% to $12.37 on 2.1x normal volume
- Closed at $12.37, -2.98% vs the prior close of $12.75. Day range $12.04–$13.22, opened at $12.50.
- Volume was 7.95M shares, 2.1x its 50-day average of 3.86M — unusually heavy trading.
- Price is +2.3% vs its 50-day average ($12.09) and -4.0% vs its 200-day average ($12.89).
- 52-week range $7.95–$28.25; today's close sits at 22% of that range, 56.2% below the 52-week high.
Oct 5, 2026 — NTLA jumps 4.0% to $12.75, a 1-month high, 5 up days in a row
- Closed at $12.75, +4.00% vs the prior close of $12.26. Day range $11.85–$12.88, opened at $12.35.
- Volume was 4.96M shares, 1.3x its 50-day average of 3.83M.
- Price is +5.7% vs its 50-day average ($12.06) and -0.9% vs its 200-day average ($12.87).
- 52-week range $7.95–$28.25; today's close sits at 24% of that range, 54.9% below the 52-week high.
- That makes 5 straight gains.
Oct 2, 2026 — NTLA rises 1.2% to $12.26, 4 up days in a row
- Closed at $12.26, +1.16% vs the prior close of $12.12. Day range $12.10–$12.77, opened at $12.42.
- Volume was 4.50M shares, 1.2x its 50-day average of 3.82M.
- Price is +2.0% vs its 50-day average ($12.02) and -4.6% vs its 200-day average ($12.85).
- 52-week range $7.95–$28.25; today's close sits at 21% of that range, 56.6% below the 52-week high.
- That makes 4 straight gains.
NTLA latest news & SEC filings
Every SEC filing by or about NTLA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 6, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Dube Michael P sold 1,864 shares at $12.43 (≈$23.17K) on Oct 2, 2026; now holds 65,022
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 5, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 8, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 4, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 24, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Leonard John M sold 2,785 shares at $13.00 (≈$36.20K) on Aug 21, 2026
- Leonard John M sold 19,890 shares at $12.60 (≈$250.61K) on Aug 20, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 20, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 7, 2026 · SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $7.66M (prior year $14.24M) (-46.2% vs Jun 30, 2025)
- Net income: -$106.63M (prior year -$101.25M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.80 (prior year -$0.98) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 24, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Dulac Edward J Iii sold 8,111 shares at $11.25 (≈$91.25K) on Jul 22, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 6, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Dube Michael P sold 2,641 shares at $16.78 (≈$44.32K) on Jul 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Things to know before you trade NTLA
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Apr 30, 2026, Feb 26, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.03% (largest 7.6%). That is a volatile stock.
- Liquidity: about 5.98M shares (≈$67.77M) trade per day on average.
- 52-week position: $11.34 vs a range of $7.95–$28.25 (17% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 1 open-market buys, 19 sales; latest: John M Leonard sold 2,785 shares on Aug 21, 2026.
- Latest filings: 8-K Sep 8, 2026; 8-K Sep 4, 2026; 10-Q Aug 6, 2026.
- Share count: 140.13M shares outstanding (Jul 31, 2026), +30.5% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: In Vitro & In Vivo Diagnostic Substances.
NTLA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 11.33 | 11.82 | 11.10 | 11.34 | 6.52M |
| Oct 14, 2026 | 11.83 | 11.87 | 11.28 | 11.43 | 5.44M |
| Oct 13, 2026 | 12.30 | 12.48 | 11.81 | 11.91 | 5.18M |
| Oct 12, 2026 | 13.08 | 13.23 | 12.56 | 12.58 | 4.38M |
| Oct 9, 2026 | 12.36 | 13.27 | 11.93 | 13.07 | 8.15M |
| Oct 8, 2026 | 11.90 | 12.64 | 11.76 | 12.60 | 13.97M |
| Oct 7, 2026 | 12.08 | 12.41 | 11.70 | 11.71 | 8.30M |
| Oct 6, 2026 | 12.50 | 13.22 | 12.04 | 12.37 | 7.95M |
| Oct 5, 2026 | 12.35 | 12.88 | 11.85 | 12.75 | 4.96M |
| Oct 2, 2026 | 12.42 | 12.77 | 12.10 | 12.26 | 4.50M |
| Oct 1, 2026 | 11.98 | 12.65 | 11.82 | 12.12 | 7.45M |
| Sep 30, 2026 | 11.96 | 12.23 | 11.75 | 12.06 | 5.31M |
| Sep 29, 2026 | 11.49 | 12.05 | 11.42 | 12.03 | 5.01M |
| Sep 28, 2026 | 11.72 | 11.80 | 11.33 | 11.42 | 3.29M |
| Sep 25, 2026 | 12.33 | 12.33 | 11.66 | 11.75 | 2.98M |
| Sep 24, 2026 | 12.13 | 12.21 | 11.62 | 12.16 | 4.81M |
| Sep 23, 2026 | 12.72 | 12.85 | 11.96 | 12.33 | 5.03M |
| Sep 22, 2026 | 12.27 | 12.97 | 12.14 | 12.69 | 3.92M |
| Sep 21, 2026 | 12.50 | 12.65 | 12.14 | 12.22 | 3.73M |
| Sep 18, 2026 | 12.15 | 12.47 | 11.86 | 12.14 | 8.62M |
About Intellia Therapeutics
Intellia Therapeutics (NTLA) is listed on the Nasdaq and classified by the SEC under “In Vitro & In Vivo Diagnostic Substances”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1652130.
NTLA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Muna Bhanji | Director | Jun 10, 2026 |
| William J Chase | Director | Jun 10, 2026 |
| Fred E Cohen | Director | Jun 10, 2026 |
| Jesse Goodman | Director | Jun 10, 2026 |
| Brian Goff | Director | Jun 10, 2026 |
| Georgia Keresty | Director | Jun 10, 2026 |
| John M Leonard | President and CEO | Aug 24, 2026 |
| Frank Verwiel | Director | Jun 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James Basta | EVP, General Counsel | Mar 3, 2026 |
| Eliana Clark | EVP, Chief Technical Officer | Mar 3, 2026 |
| Michael P Dube | VP, Chief Accounting Officer | Jul 6, 2026 |
| Edward J Iii Dulac | EVP, Chief Financial Officer | Jul 24, 2026 |
| John M Leonard | President and CEO | Aug 24, 2026 |
| David Lebwohl | EVP, Chief Medical Officer | Mar 3, 2026 |
| Birgit C Schultes | EVP, Chief Scientific Officer | Mar 3, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 21, 2026 | John M Leonard | Sale | 2,785 | $13.00 |
| Aug 20, 2026 | John M Leonard | Sale | 19,890 | $12.60 |
| Jul 22, 2026 | Edward J Iii Dulac | Sale | 8,111 | $11.25 |
| Jul 2, 2026 | Edward J Iii Dulac | Sale | 4,677 | $18.00 |
| Jul 1, 2026 | Michael P Dube | Sale | 2,641 | $16.78 |
| Mar 2, 2026 | Eliana Clark | Sale | 607 | $13.78 |
| Mar 2, 2026 | James Basta | Sale | 1,211 | $13.78 |
| Jan 5, 2026 | Birgit C Schultes | Sale | 8,508 | $9.21 |
| Jan 5, 2026 | Eliana Clark | Sale | 9,515 | $9.21 |
| Jan 5, 2026 | Fred E Cohen | Buy | 150,000 | $9.35 |
| Jan 5, 2026 | John M Leonard | Sale | 34,146 | $9.21 |
| Jan 5, 2026 | James Basta | Sale | 10,397 | $9.21 |
| Jan 5, 2026 | Edward J Iii Dulac | Sale | 6,379 | $9.21 |
| Jan 5, 2026 | Michael P Dube | Sale | 2,989 | $9.21 |
| Jan 5, 2026 | David Lebwohl | Sale | 11,903 | $9.21 |
NTLA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $67.67M | $-412.69M | -3.81 | $-394.74M |
| Dec 31, 2024 | $57.88M | $-519.02M | -5.25 | $-348.88M |
| Dec 31, 2023 | $36.27M | $-481.19M | -5.42 | $-394.09M |
| Dec 31, 2022 | $52.12M | $-474.19M | -6.16 | $-333.29M |
| Dec 31, 2021 | $33.05M | $-267.89M | -3.78 | $-225.03M |
Latest balance sheet: total assets $857.16M, total liabilities $129.46M, cash $106.13M (as of Jun 30, 2026).
NTLA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $11.24 |
| May 11, 2026 | 8-K Item 2.02 (results) | $14.42 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $13.48 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $14.28 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $12.32 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $11.46 |
| May 8, 2025 | 8-K Item 2.02 (results) | $8.28 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $10.86 |
| Jan 10, 2025 | 8-K Item 2.02 (results) | $10.20 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $16.00 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · In Vitro & In Vivo Diagnostic Substances
Idexx Laboratories (IDXX)Lantheus (LNTH)Neogen (NEOG)Celldex Therapeutics (CLDX)QuidelOrtho (QDEL)Achieve Life Sciences (ACHV)Myriad Genetics (MYGN)Alpha Teknova (TKNO)Insight Molecular Diagnostics (IMDX)Volitionrx (VNRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on NTLA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.